Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
30.18 USD | +1.80% | +10.18% | -10.78% |
May. 08 | Needham Adjusts Price Target on Pacira BioSciences to $43 From $45, Keeps Buy Rating | MT |
May. 07 | Transcript : Pacira BioSciences, Inc., Q1 2024 Earnings Call, May 07, 2024 |
Financials (USD)
Sales 2024 * | 695M | Sales 2025 * | 762M | Capitalization | 1.38B |
---|---|---|---|---|---|
Net income 2024 * | 59M | Net income 2025 * | 92M | EV / Sales 2024 * | 2.1 x |
Net Debt 2024 * | 78.88M | Net cash position 2025 * | 135M | EV / Sales 2025 * | 1.63 x |
P/E ratio 2024 * |
24.4
x | P/E ratio 2025 * |
15.5
x | Employees | 712 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.69% |
Latest transcript on Pacira BioSciences, Inc.
1 day | +1.89% | ||
1 week | +10.18% | ||
Current month | +14.68% | ||
1 month | +5.55% | ||
3 months | +4.60% | ||
6 months | +5.88% | ||
Current year | -10.78% |
Managers | Title | Age | Since |
---|---|---|---|
Frank Lee
CEO | Chief Executive Officer | 56 | Jan. 01 |
Charles Reinhart
DFI | Director of Finance/CFO | 63 | 11-10-31 |
Jonathan Slonin
CTO | Chief Tech/Sci/R&D Officer | 49 | 21-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Gary Pace
BRD | Director/Board Member | 76 | 08-05-31 |
Paul Hastings
CHM | Chairman | 64 | 11-06-01 |
Andreas Wicki
BRD | Director/Board Member | 64 | 06-11-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.24% | 0 M€ | -3.17% | - | |
0.18% | 0 M€ | +2.79% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-09 | 30.08 | +1.43% | 279 732 |
24-05-08 | 29.65 | +11.84% | 1,961,588 |
24-05-07 | 26.51 | +0.04% | 734,470 |
24-05-06 | 26.5 | -2.61% | 733,744 |
24-05-03 | 27.21 | -0.40% | 247,316 |
Delayed Quote Nasdaq, May 09, 2024 at 10:55 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.78% | 1.38B | |
+33.07% | 698B | |
+26.51% | 568B | |
-4.33% | 358B | |
+19.18% | 328B | |
+4.06% | 283B | |
+16.51% | 238B | |
+6.68% | 203B | |
-9.08% | 198B | |
+7.70% | 165B |
- Stock Market
- Equities
- PCRX Stock